Skip to main content

Jessica Hagen

By Jessica Hagen | 12:56 pm | October 21, 2022
When determining approval for Breakthrough Device designation, the FDA will consider whether the device addresses present health inequities.
By Jessica Hagen | 03:22 pm | October 20, 2022
The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.
By Jessica Hagen | 11:21 am | October 20, 2022
A study published in JAMA Network Open found that increased EHR use among primary care physicians was associated with improved patient A1c levels, hypertension control and breast cancer screening rates.
By Jessica Hagen | 03:04 pm | October 19, 2022
The multinational pharma company will now be able to access Tempus' de-identified patient data.
By Jessica Hagen | 05:13 pm | October 18, 2022
The newest offering is spirometry testing to evaluate patients for chronic obstructive pulmonary disease.
By Jessica Hagen | 02:29 pm | October 18, 2022
The company will distribute AlertWatch to hospitals in the U.S. as part of its strategic partnership with Medtronic.
By Jessica Hagen | 02:43 pm | October 17, 2022
The company will use the funds to expand its platform and accelerate global commercialization.
By Jessica Hagen | 12:09 pm | October 17, 2022
During its earnings call this week, Walgreens' CEO said the company would invest in an organization currently achieving EBITDA.
By Jessica Hagen | 01:08 pm | October 14, 2022
Consumers can access HealthTap's virtual health services via a TV and a connected camera.
By Jessica Hagen | 11:19 am | October 14, 2022
The company will expand its network and platform and increase R&D investments.